Daniela A. Ferraro - Concepedia

Author

Daniela A. Ferraro

Also Known As

D A Ferraro, D Ferraro, D. A. Ferraro, D. Ferraro, D.A. Ferraro, DMN Ferraro, Daniela A Ferraro, Daniela A. Ferraro, Daniela Aleida Ferraro, Daniela Ferraro

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Zurich University of Zurich Kantonsspital Baden University of Messina Universidade de São Paulo

About

Daniela A. Ferraro is an author at University Hospital of Zurich specializing in medicine, cell biology, and radiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	887
2	Engineering	4	4	212
3	Health Sciences	4	4	175
4	Biochemistry	4	4	239
5	Natural Sciences	1	1	52

Daniela A. Ferraro

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer Marco Archetti, Daniela A. Ferraro, Gerhard Christofori Proceedings of the National Academy of Sciences	2015	168
Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS) Daniela A. Ferraro, Simona Corso, E Fasano, Oncogene Tumor BiologySignaling PathwayBiochemistryOncogenic AgentMedicine	2006	131
Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks – Initial results Moritz Schwyzer, Daniela A. Ferraro, Urs J. Muehlematter, Lung Cancer Deep Neural NetworksEngineeringMedical ImagingMedical Image ComputingBiomedical Imaging	2018	117
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR Daniela A. Ferraro, Nadège Gaborit, Ruth Maron, Proceedings of the National Academy of Sciences Breast OncologyOncologyMedicineImmunologyImmune Checkpoint Inhibitor	2013	110
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression Fresia Pareja, Daniela A. Ferraro, Charles Rubin, Oncogene Tumor BiologyMedicineCancer BiologyTumor SuppressorOncology	2011	103
First Clinicopathologic Evidence of a Non–PSMA-Related Uptake Mechanism for <sup>68</sup>Ga-PSMA-11 in Salivary Glands Niels J. Rupp, Christoph A. Umbricht, Daniele Antonio Pizzuto, Journal of Nuclear Medicine	2019	93
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns Jan H. Rüschoff, Daniela A. Ferraro, Urs J. Muehlematter, European Journal of Nuclear Medicine and Molecular Imaging	2021	89
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with <sup>68</sup>Ga-PSMA-11-PET Daniela A. Ferraro, Jan H. Rüschoff, Urs J. Muehlematter, Theranostics	2020	86
Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study Daniela A. Ferraro, Anton S. Becker, Benedikt Kranzbühler, European Journal of Nuclear Medicine and Molecular Imaging	2021	83
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer Nir Ben‐Chetrit, David Chetrit, Roslin Russell, Science Signaling Tumor BiologySystems BiologySynaptojanin 2Breast OncologyMedicine	2015	77

Page 1